Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Celldex Therapeutics (CLDX) Gains from Investment Securities (2016 - 2025)

Celldex Therapeutics has reported Gains from Investment Securities over the past 16 years, most recently at $289955.0 for Q3 2025.

  • Quarterly results put Gains from Investment Securities at $289955.0 for Q3 2025, down 88.0% from a year ago — trailing twelve months through Dec 2025 was -$9000.0 (up 99.05% YoY), and the annual figure for FY2025 was $2.2 million, down 71.43%.
  • Gains from Investment Securities for Q3 2025 was $289955.0 at Celldex Therapeutics, down from $2.0 million in the prior quarter.
  • Over the last five years, Gains from Investment Securities for CLDX hit a ceiling of $6.4 million in Q4 2023 and a floor of -$964000.0 in Q4 2021.
  • Median Gains from Investment Securities over the past 5 years was $1.0 million (2023), compared with a mean of $1.4 million.
  • Biggest five-year swings in Gains from Investment Securities: skyrocketed 637992.4% in 2023 and later crashed 100.4% in 2025.
  • Celldex Therapeutics' Gains from Investment Securities stood at -$964000.0 in 2021, then skyrocketed by 99.9% to -$1000.0 in 2022, then skyrocketed by 637992.4% to $6.4 million in 2023, then tumbled by 100.06% to -$4000.0 in 2024, then surged by 7348.88% to $289955.0 in 2025.
  • The last three reported values for Gains from Investment Securities were $289955.0 (Q3 2025), $2.0 million (Q2 2025), and -$4000.0 (Q1 2025) per Business Quant data.